The Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) drugs in development market research report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued products.

GlobalData tracks 49 drugs in development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by 50 companies/universities/institutes. The top development phase for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) is phase ii with 18 drugs in that stage. The Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline has 47 drugs in development by companies and two by universities/ institutes. Some of the companies in the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline products market are: Takeda Pharmaceutical, 3SBio and Novartis.

The key targets in the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline products market include Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL), Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2), and Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2).

The key mechanisms of action in the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline product include Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Agonist with ten drugs in Pre-Registration. The Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline products include four routes of administration with the top ROA being Subcutaneous and 11 key molecule types in the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline products market including Small Molecule, and Monoclonal Antibody.

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) overview

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose, and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on the lower legs.

For a complete picture of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.